Tolerability of up to 200 days of prophylaxis with valganciclovir oral solution and/or film-coated tablets in pediatric kidney transplant recipients at risk of cytomegalovirus disease
| Autor: | Jane Ives, H. T. Silva, R. Reyes-Acevedo, D. Bradley, C. Benchimol, G. Varela-Fascinetto, M. Genevray |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Graft Rejection
Male medicine.medical_specialty Adolescent Anemia Biopsy Urinary system 030232 urology & nephrology Administration Oral Renal function 030230 surgery Neutropenia Antiviral Agents Gastroenterology Drug Administration Schedule 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Valganciclovir Child Ganciclovir Transplantation Leukopenia business.industry Infant medicine.disease Kidney Transplantation Transplant Recipients Surgery Treatment Outcome Upper respiratory tract infection Tolerability Child Preschool Cytomegalovirus Infections Mutation Pediatrics Perinatology and Child Health Female Tablets Enteric-Coated medicine.symptom business medicine.drug |
| Zdroj: | Pediatric Transplantation. 21:e12833 |
| ISSN: | 1397-3142 |
| Popis: | This multicenter, open-label study evaluated the tolerability of extended prophylaxis with valganciclovir in pediatric kidney transplant recipients at risk of CMV disease. Fifty-six patients aged 4 months to 16 years received once-daily valganciclovir oral solution and/or tablets, dosed by BSA and renal function, for up to 200 days. The most common AEs on treatment were upper respiratory tract infection (33.9%), urinary tract infection (33.9%), diarrhea (32.1%), leukopenia (25.0%), neutropenia (23.2%), and headache (21.4%). There were fewer AEs during days 101-228 vs days 1-100. Twenty-seven patients (48.2%) had treatment-related AEs during valganciclovir treatment, most commonly leukopenia (21.4%), neutropenia (19.6%), anemia (7.1%), and tremor (5.4%). Treatment-related serious AEs were reported for nine patients (16.1%) and six withdrew due to AEs. Viremia was centrally confirmed in 10 patients; there was no confirmed CMV disease. One patient tested positive for a resistance mutation (UL97 L595F). Biopsy-proven acute rejection occurred in six patients (10.7%), but no graft loss or deaths occurred. In conclusion, up to 200 days of valganciclovir prophylaxis in pediatric kidney allograft recipients showed a safety profile consistent with that established in adult transplant patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text